CUE

CUE BIOPHARMA INC

1 day chart

About CUE

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Buy US stocks in Australia starting with CUE. Open an account and start investing today!

Market Capitalisation

$168.83M

Price-earnings ratio

Dividend yield

0.00%

Volume

453.92K

High today

$4.05

Low today

$3.63

Open price

$4.00

52-week high

$5.12

52-week low

$2.18

CUE FAQs

Can I buy CUE shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy CUE shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of CUE BIOPHARMA INC?

One share of CUE BIOPHARMA INC is valued at $3.91.

What is the ticker symbol for CUE BIOPHARMA INC?

The ticker symbol for CUE BIOPHARMA INC is CUE.

How do I buy CUE shares in Australia?

To buy CUE stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in CUE

What is the 52-week high for CUE BIOPHARMA INC stock?

The CUE BIOPHARMA INC 52-week high stock price is $5.12.

What is the 52-week low for CUE BIOPHARMA INC stock?

The CUE BIOPHARMA INC 52-week low stock price is $2.18.

What is the market capitalisation of CUE BIOPHARMA INC CUE?

As of 28/05/2023 CUE BIOPHARMA INC has a market cap of $169M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.